BFM
PTCT icon

Boothbay Fund Management’s PTC Therapeutics PTCT Stock Holding History

Boothbay Fund Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-83,200
Closed -$5.11M – 2277
2025
Q3 		$5.11M Buy
+83,200
New +$4.33M 0.07% 313
2023
Q2 		– Sell
-88,000
Closed -$4.26M – 2206
2023
Q1 		$4.26M Buy
+88,000
New +$4.02M 0.09% 308
2022
Q3 		– Sell
-30,800
Closed -$1.23M – 2535
2022
Q2 		$1.23M Buy
+30,800
New +$1.08M 0.03% 730
2018
Q4 		– Sell
-239
Closed -$1.12M – 845
2018
Q3 		$1.12M Buy
+239
New +$9.89K 0.11% 179

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Boothbay Fund Management's PTCT Position: Q1 2026 in Review

Boothbay Fund Management sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 39,735 shares — an estimated $3.02M sold.

Boothbay Fund Management first reported a position in PTCT in Q1 2019 and held it in 10 quarters. The position peaked at $6.79M in Q3 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Boothbay Fund Management reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 39,735 PTC Therapeutics shares in Q1 2026, an estimated $3.02M.
  • Boothbay Fund Management first reported a position in PTC Therapeutics in Q1 2019 and held it in 10 quarters.
  • Boothbay Fund Management's PTC Therapeutics position peaked at $6.79M in Q3 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.